Dong-A ST Co., Ltd. (170900.KS)
KRW 45350.0
(0.78%)
KRW 45350.0
(0.78%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 631.91 Billion KRW | 35.14% |
| 2022 | 467.61 Billion KRW | 1.74% |
| 2021 | 459.6 Billion KRW | 35.75% |
| 2020 | 338.57 Billion KRW | -6.71% |
| 2019 | 362.91 Billion KRW | -1.73% |
| 2018 | 369.3 Billion KRW | 15.94% |
| 2017 | 318.52 Billion KRW | -33.28% |
| 2016 | 477.39 Billion KRW | -6.35% |
| 2015 | 509.76 Billion KRW | -14.11% |
| 2014 | 593.52 Billion KRW | 20.55% |
| 2013 | 492.35 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 754.91 Billion KRW | 17.36% |
| 2024 Q1 | 643.23 Billion KRW | 1.79% |
| 2023 Q4 | 631.91 Billion KRW | 12.03% |
| 2023 Q1 | 484.96 Billion KRW | 3.71% |
| 2023 FY | 631.91 Billion KRW | 35.14% |
| 2023 Q3 | 564.05 Billion KRW | 1.62% |
| 2023 Q2 | 555.06 Billion KRW | 14.45% |
| 2022 FY | 467.61 Billion KRW | 1.74% |
| 2022 Q1 | 527.54 Billion KRW | 14.78% |
| 2022 Q2 | 521.35 Billion KRW | -1.17% |
| 2022 Q4 | 467.61 Billion KRW | -11.43% |
| 2022 Q3 | 527.96 Billion KRW | 1.27% |
| 2021 Q4 | 459.6 Billion KRW | -4.77% |
| 2021 Q2 | 355.07 Billion KRW | -0.13% |
| 2021 FY | 459.6 Billion KRW | 35.75% |
| 2021 Q1 | 355.52 Billion KRW | 5.01% |
| 2021 Q3 | 482.63 Billion KRW | 35.93% |
| 2020 Q1 | 372.69 Billion KRW | 2.69% |
| 2020 FY | 338.57 Billion KRW | -6.71% |
| 2020 Q4 | 338.57 Billion KRW | -1.16% |
| 2020 Q3 | 342.55 Billion KRW | -0.24% |
| 2020 Q2 | 343.37 Billion KRW | -7.87% |
| 2019 Q3 | 415.74 Billion KRW | 1.0% |
| 2019 Q4 | 362.91 Billion KRW | -12.71% |
| 2019 Q1 | 383.93 Billion KRW | 3.96% |
| 2019 FY | 362.91 Billion KRW | -1.73% |
| 2019 Q2 | 411.61 Billion KRW | 7.21% |
| 2018 FY | 369.3 Billion KRW | 15.94% |
| 2018 Q4 | 369.3 Billion KRW | 6.63% |
| 2018 Q3 | 346.33 Billion KRW | -2.08% |
| 2018 Q2 | 353.68 Billion KRW | -5.14% |
| 2018 Q1 | 372.85 Billion KRW | 17.06% |
| 2017 Q1 | 442.37 Billion KRW | -7.34% |
| 2017 Q2 | 417.84 Billion KRW | -5.55% |
| 2017 Q3 | 332.7 Billion KRW | -20.37% |
| 2017 Q4 | 318.52 Billion KRW | -4.26% |
| 2017 FY | 318.52 Billion KRW | -33.28% |
| 2016 Q2 | 461.31 Billion KRW | -4.72% |
| 2016 FY | 477.39 Billion KRW | -6.35% |
| 2016 Q4 | 477.39 Billion KRW | 9.73% |
| 2016 Q3 | 435.05 Billion KRW | -5.69% |
| 2016 Q1 | 484.17 Billion KRW | -5.02% |
| 2015 Q4 | 509.76 Billion KRW | -1.7% |
| 2015 FY | 509.76 Billion KRW | -14.11% |
| 2015 Q3 | 518.6 Billion KRW | -11.33% |
| 2015 Q2 | 584.84 Billion KRW | -1.43% |
| 2015 Q1 | 593.3 Billion KRW | -0.04% |
| 2014 FY | 593.52 Billion KRW | 20.55% |
| 2014 Q1 | 501.83 Billion KRW | 1.92% |
| 2014 Q2 | 530.61 Billion KRW | 5.74% |
| 2014 Q3 | 529.7 Billion KRW | -0.17% |
| 2014 Q4 | 593.52 Billion KRW | 12.05% |
| 2013 Q2 | 522.38 Billion KRW | 0.0% |
| 2013 Q3 | 513.57 Billion KRW | -1.69% |
| 2013 Q4 | 492.35 Billion KRW | -4.13% |
| 2013 FY | 492.35 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -300.815% |
| Yuhan Corporation | 712.33 Billion KRW | 11.29% |
| Yuhan Corporation | 712.33 Billion KRW | 11.29% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -711.623% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -711.623% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -711.623% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 10.633% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -160.204% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 32.038% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -66.469% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -66.469% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -66.469% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -3875.669% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 0.096% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -740.633% |
| HANDOK Inc. | 449.7 Billion KRW | -40.517% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | -32.251% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -637.609% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -203.516% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -186.315% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -1634.295% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -159.263% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -361.356% |
| Boryung Corporation | 373.1 Billion KRW | -69.364% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -803.149% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -308.909% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -206.939% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -206.939% |
| Suheung Co., Ltd. | 516.66 Billion KRW | -22.305% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | -28.957% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -1080.512% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1368.909% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -327.562% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -696.848% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -696.848% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -602.395% |
| CKD Bio Corp. | 170.76 Billion KRW | -270.057% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 26.353% |
| JW Holdings Corporation | 827.51 Billion KRW | 23.637% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -151.606% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 25.817% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | -7.689% |
| JW Lifescience Corporation | 96.44 Billion KRW | -555.216% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -44.604% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -91.318% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -797.586% |